GlassScriptPhysician profile
Amanda Mason
NPI 1104365964
$1,182.24
in general payments reported to CMS, 2019-2025
22 companies · $765 in 2025
The $765 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.26 · 2022: $74.80 · 2023: $124 · 2024: $196 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $240.09 | 2024-2025 | |
| Amgen INC. | $119.57 | 2023-2024 | Evenity, Prolia |
| Abbott Laboratories | $105.82 | 2021-2025 | Eterna, Octrode |
| Nalu Medical, INC. | $92.66 | 2025 | Nalu Neurostimulation System |
| Lundbeck LLC | $81.92 | 2025 | Vyepti |
| Boston Scientific Corporation | $59.93 | 2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $58.28 | 2025 | Belbuca |
| Pfizer INC. | $52.68 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $51.10 | 2024-2025 | |
| Medtronic, INC. | $39.51 | 2024 | Intellis Adaptivestim |
| Protega Pharmaceutials INC | $37.87 | 2025 | Roxybond |
| Kowa Pharmaceuticals America, INC. | $36.74 | 2022-2023 | Seglentis |
| Bioventus LLC | $34.31 | 2022-2024 | Nexus-10 Mkii |
| Spr Therapeutics, INC | $28.10 | 2025 | Sprint Pns System |
| Ethicon US, LLC | $23.52 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $23.23 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Radius Health, INC. | $19.18 | 2023 | Tymlos |
| Ossur Americas, INC. | $18.51 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.35 | 2025 | Horizant |
| Globus Medical, INC. | $15.37 | 2025 | Senza |
| Ibsa Pharma INC. | $14.03 | 2024 | Licart, Tirosint |
| Saluda Medical Americas, INC. | $13.47 | 2025 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.